Apricus Biosciences, Inc.


Apricus Biosciences Provides Corporate Update, Fourth Quarter and Full Year 2016 Financial Results

SAN DIEGO, 2017-03-13 21:17 CET (GLOBE NEWSWIRE) --

Sale of Ex-U.S. Vitaros Assets and Rights to Ferring Pharmaceuticals Strengthens Financial Position

Vitaros U.S. NDA Re-Submission on Track for Third Quarter 2017

Conference Call / Webcast Today, Monday, March13, 2017 at 4:30 p.m. ET

Apricus Biosciences, Inc. (Nasdaq:APRI), a biopharmaceutical company advancing innovative medicines in urology and rheumatology, today reported financial results for the fourth quarter and full year of 2016 and provided a corporate update on its priorities for 2017.

“Last week, we announced the divestiture of our ex-U.S. Vitaros interests to Ferring Pharmaceuticals. The closing of this transaction will allow us to focus our attention on the U.S. Vitaros NDA resubmission in the third quarter of this year, and advancing the RayVa clinical development program,” stated Richard W. Pascoe, Chief Executive Officer. “We continue to believe in the tremendous value that our pipeline potentially offers to patients, healthcare providers and shareholders as we look ahead and we are committed to working with Ferring to ensure a smooth transition of the Vitaros product outside of the United States. Importantly, this transaction creates a more streamlined, capital efficient organization with the potential to deliver on multiple regulatory, clinical and business development milestones over the next twelve months.”

Strategic Priorities

Apricus continues to focus on achieving the following key strategic objectives:


· Continue implementation of the U.S. regulatory approval strategy to address the safety issues raised by the FDA in the original Vitaros NDA submission. Apricus anticipates a meeting with the FDA’s Office of Product Quality in the second quarter of 2017 to confirm the necessary device engineering and compliance requirements, following which the Company intends to resubmit the Vitaros NDA. An FDA approval decision is expected after a six month review period;

· Support the Ferring knowledge transfer, to ensure a smooth transition of certain ex-U.S. assets and rights related to Vitaros in an effort to ensure that Vitaros continues to grow as a global brand.


· Explore Orphan Drug Designation in the U.S. and EU;

· Finalize clinical trial protocol and clinical trial material formulation work needed to initiate a Phase 2b study; and

· Explore global or regional partnerships prior to initiating the Phase 2b study.


· Reduce operating expenses by approximately 30% in 2017 as compared to 2016 operating expenses;

· Regain compliance with the minimum $2.5 million shareholder equity requirement as required for continued listing on The NASDAQ Capital Market under NASDAQ Listing Rule 5550(b)(2) on or before May 30, 2017.

Fourth Quarter and Full Year Financial Results

Total revenues for the quarter and year to date periods ended December31, 2016 were $0.4 million and $5.8 million, respectively, as compared to $2.6 million and $4.8 million for the quarter and year to date periods ended December 31, 2015, respectively. The decrease during the fourth quarter comparison was primarily due to license fee revenue of $2.25 million recognized in the fourth quarter of 2015 associated with the Company’s former partner, Ferring. The increase during the full year comparison was primarily due to increased license fee revenue and royalty revenue in the current year. Net loss for the quarter ended December31, 2016 was $0.3 million, or loss per share of $0.04, compared to a net loss of $2.3 million, or $0.05 per share for the fourth quarter of 2015. Net loss for the year ended December 31, 2016 was $7.4 million, or loss per share of $1.14, compared to a net loss of $19.0 million, or loss per share of $3.83 for the year ended December 31, 2015. The reduction in the net loss during the current year periods as compared to the prior year periods is a result of decreased research and development expenses as well as decreased general and administrative expenses. Also reducing the net loss for the quarter and year ended December31, 2016 was a non-cash change in the fair value of the Company’s warrant liabilities in the amount of $2.4 million and $7.5 million, respectively.

As of March8, 2017, the Company’s cash totaled $5.4 million, compared to $2.1 million as of December31, 2016.

Conference Call Details

Apricus will host a live conference call and webcast today at 4:30 p.m. Eastern Time to discuss the Company’s financial results and provide a corporate update. To participate by telephone, please dial (855) 780-7196 (Domestic) or (631) 485-4867 (International). The conference ID number is 85861485. The live and archived audio webcast can be accessed through the Investors Relations’ section of the Company’s website Please log in approximately five to ten minutes before the event to ensure a timely connection. The archived webcast will be available for 30 days following the live call.

About Apricus Biosciences, Inc.

Apricus Biosciences, Inc. (APRI) is a biopharmaceutical company advancing innovative medicines in urology and rheumatology. Apricus has two product candidates currently in development. Vitaros is a product candidate in the United States for the treatment of erectile dysfunction, which is in-licensed from Warner Chilcott Company, Inc., now a subsidiary of Allergan plc (Allergan). RayVa is our product candidate in Phase 2 development for the treatment of the circulatory disorder Raynaud’s phenomenon, secondary to scleroderma, for which we own worldwide rights.

For further information on Apricus, visit

Vitarosis Apricus’ trademark in the United States, which is pending registration and subject to the agreement with Allergan. Vitaros®is a registered trademark of Ferring B.V. in certain countries outside of the United States. RayVais Apricus’ trademark, which is registered in certain countries throughout the world and pending registration in the United States.

Forward Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act, as amended. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things: Apricus’ ability to transition its ex-U.S. assets and rights related to Vitaros to Ferring; the timing and significance of the meeting with the FDA regarding device engineering and compliance; the timing of regulatory submission and approval of Vitaros in the United States, if any; Apricus’ plans for life-cycle development programs for Vitaros; Apricus’ development and partnering plans for RayVa; Apricus’ plans to reduce operating expenses and achieve profitability, including projected 2017 cost savings; and Apricus’ strategic objectives, including efforts to regain compliance with NASDAQ listing standards. Actual results could differ from those projected in any forward-looking statements due to a variety of reasons that are outside the control of Apricus, including, but not limited to: the risk that Apricus fails to provide the transition services as required by the transition services agreement with Ferring; the risk that the cost and other negative effects related to the reduction of Apricus’ workforce may be greater than anticipated; the risk that Apricus may not realize the benefits expected from its workforce reduction and other cost control measures; competition in the erectile dysfunction market and other markets in which Apricus operates; Apricus’ ability to obtain FDA and other requisite governmental approval for Vitaros; Apricus’ ability to further develop Vitaros, such as delivery device improvements; Apricus' ability to carry out further clinical studies for Vitaros, if required, as well as the timing and success of the results of such studies; Apricus’ ability to achieve U.S. and EU Orphan Designation for RayVa; the failure to meet NASDAQ continued listing requirements which could result in Apricus’ common stock being delisted from the exchange; Apricus’ ability to retain and attract key personnel; Apricus’ ability to raise additional funding that it may need to continue to pursue its commercial and business development plans; Apricus’ ability to secure an ex-U.S. strategic partner for RayVa; and market conditions. These forward-looking statements are made as of the date of this press release, and Apricus assumes no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Readers are urged to read the risk factors set forth in Apricus’ most recent annual report on Form 10-K, subsequent quarterly reports filed on Form 10-Q, and other filings made with the SEC. Copies of these reports are available from the SEC’s website atwww.sec.govor without charge from Apricus.

(Financial Information to Follow)

Selected Financial Information
Consolidated Statements of Operations
(In thousands, except per share amounts)
Year Ended
December 31,
2016 2015
License fee revenue $ 4,000 $ 3,600
Royalty revenue 1,088 650
Product sales 675 589
Total revenue 5,763 4,839
Cost of goods sold 511 922
Cost of Sandoz rights 3,380
Gross profit 1,872 3,917
Research & development expense 6,831 14,649
General & administrative expense 8,434 10,516
Loss on disposal of assets 14 102
Total operating expense 15,279 25,267
Other income 5,974 2,327
Net loss $ (7,433 ) $ (19,023 )
Basic and diluted loss per common share $ (1.14 ) $ (3.83 )
Weighted average common shares outstanding used for basic and diluted loss per share 6,516,662 4,972,858

Consolidated Balance Sheets
(In thousands)
December 31,
December 31,
Cash $ 2,087 $ 3,887
Other current assets 1,547 2,330
Property and equipment, net 1,006 1,290
Other long term assets 60 274
Total assets $ 4,700 $ 7,781
Current liabilities $ 4,644 $ 6,146
Notes payable 6,650 9,401
Warrant liabilities 846 1,841
Deferred revenue 137
Other long term liabilities 76 200
Stockholders’ deficit (7,516 ) (9,944 )
Total liabilities and stockholders’ deficit $ 4,700 $ 7,781

Information om Globenewswire

Nikolaj Plads 6
1007 København K

+45 3377 0377